[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1975

Cyclophosphamide Therapy for Rheumatoid Arthritis

Author Affiliations

From the Arthritis Division, Department of Medicine, University of Colorado School of Medicine, Denver. Dr. Bartholomew is now at Texas Technical University School of Medicine, Dr. Strong is now at the Holbrook-Hill Medical Group, Tucson, Ariz, and Dr. Recart is with the University of Concepcion Medical School, Concepcion, Chile.

Arch Intern Med. 1975;135(6):789-793. doi:10.1001/archinte.1975.00330060033004
Abstract

Cyclophosphamide in high doses was given for six months to 19 patients with rheumatoid arthritis. A second group of patients with rheumatoid arthritis whose conditions were stable on low-dose prednisone received in addition either cyclophosphamide or placebo for six months. Measurements of joint function and joint inflammation were used to estimate disease activity. Joint inflammation progressively decreased and joint function improved in the high-dose group. The low-dose cyclophosphamide-plus-prednisone group had a similar response that was different from the prednisone-plus-placebo group. Cyclophosphamide toxicity was common in the high-dose group and minimal in the low-dose-plus-prednisone group. Cyclophosphamide therapy improved the arthritis of these patients. The results were almost as good in the low-dose-plus-prednisone group, and the toxicity was much less.

×